Acasti Pharma (NASDAQ:ACST) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

Shares of ACST opened at $1.18 on Wednesday. Acasti Pharma has a fifty-two week low of $0.43 and a fifty-two week high of $3.36. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.22. The company has a market cap of $47.32 million, a P/E ratio of -1.55 and a beta of 1.35.

Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter. On average, research analysts forecast that Acasti Pharma will post -0.7 earnings per share for the current fiscal year.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Featured Article: Understanding Average Daily Trade Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.